{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-23-276640","form_type":"8-K","ticker":"GRTX","cik":"0001563577","company_name":"Galera Therapeutics, Inc.","filed_at":"2023-11-14T23:59:59+00:00","discovered_at":"2026-05-14T18:03:29.534318+00:00","generated_at":"2026-06-08T03:33:47.435093+00:00","sec_items":["2.02","9.01"],"event_type":"other_material","sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Galera Therapeutics reports Q3 loss; FDA requires new avasopasem trial; GRECO trials halted","bullets":["FDA issued Complete Response Letter for avasopasem NDA; requires an additional Phase 3 trial for resubmission.","GRECO-2 (pancreatic cancer) and GRECO-1 (NSCLC) trials halted following futility analyses.","Workforce reduced by 22 employees (~70%) in August 2023; restructuring charges of $2.3M in Q3.","Q3 2023 net loss of $15.1M ($0.33 per share) vs. $16.0M ($0.60) in Q3 2022; cash $28.4M.","Company exploring strategic alternatives including mergers, asset sales; may be required to cease operations."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-23-276640","json":"https://secwatch.observer/filing/0001193125-23-276640.json","markdown":"https://secwatch.observer/filing/0001193125-23-276640.md","text":"https://secwatch.observer/filing/0001193125-23-276640.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1563577/000119312523276640/0001193125-23-276640-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1563577/000119312523276640/d596085d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-08T03:33:47.435093+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"00c12d5499532212424390a72c30fe01b9f1de73","claim":"Galera Therapeutics, Inc. reported third quarter ended September 30, 2023 results: net income $(15.1) million, EPS $(0.33) per share.","evidence_excerpt":"Galera reported a net loss of $(15.1) million, or $(0.33) per share","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1563577/000119312523276640/0001193125-23-276640-index.htm","confidence":0.97,"family_label":"Earnings Releases","details":[{"label":"Period","value":"third quarter ended September 30, 2023"},{"label":"Net income","value":"$(15.1) million"},{"label":"EPS","value":"$(0.33) per share"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}